Rigel Pharma (Nasdaq: RIGL) announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE